IMU 0.00% 1.7¢ imugene limited

News: Imugene progressing cancer vaccine towards clinical studies

  1. Imugene (ASX:IMU) is preparing to initiate this year the clinical program for its Her-Vaxx peptide vaccine, a B-cell based immunotherapy for HER-2 positive gastric & breast cancer.

    Her-Vaxx has potential to improve upon Roche’s blockbuster Herceptin drug that generated annualised sales of $6.9 billion and targets the same biomarker.

    It was developed by one of Europe’s leading cancer institutes with about $10 million already invested in the technology.

    Charles Walker, managing director. outlined these points and many others at the February 2015 Proactive Investors Melbourne / Sydney Luncheons.

    The full presentation can be ACCESSED HERE.


watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Mkt cap ! $61.36M
Open High Low Value Volume
1.7¢ 1.7¢ 1.7¢ $59.88K 3.522M

Buyers (Bids)

No. Vol. Price($)
15 6554153 1.6¢

Sellers (Offers)

Price($) Vol. No.
1.7¢ 1073324 2
View Market Depth
Last update - 16.10pm 20/02/2019 (20 minute delay) ?
0.000 ( 0.00 %)
Open High   Low Volume
1.7¢ 1.7¢   1.6¢ 1863887
Last updated 15.50pm 20/02/2019 (live) ?
IMU (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.